##
##
##
##
##
##
##
##
##
##
##
##
||||||30.9.23|30.9.22|
|---|---|---|---|---|---|---|
||||||Unrestricted|Total|
||||||fund|funds|
|||||||as restated|
|||||Notes|||
|INCOME AND ENDOWMENTS FROM|||||||
|Donations
and legacies|||||33,023|17,303|
|Charitable
activities|||||||
|Research into and|education||on oncology||23,603|27,129|
|Investment
income|||||52,478|46,209|
|Other income|||||9,205|8,989|
|Total|||||118309|99,630|
|EXPENDITURE|ON||||||
|Raising funds|||||19&451|19,389|
|Charitable
activities|||||||
|Research into and|education||on oncology||96,222|49,652|
|Other|||||||
|Total|||||115,673|69,041|
|Net gains/(losses)|on investments||||34,115|~68,3093|
|NET INCOME/(EXPENDITURE)|||||36,811|(37,720)|
|RECONCILIATION||OF FUNDS|||||
|Total funds brought
forward|||||1,532,211|1,569,931|
|TOTAL FUNDS CARRIED FORWARD|||||1,569,022|1,532,211|
|||30.9.23|30.9.22|
|---|---|---|---|
|||Unrestricted|Total|
|||fund|funds|
||||as restated|
||Notes|||
|FIXEDASSETS||||
|Investments|12|1,293,509|1,227,599|
|CURRENT ASSETS||||
|Debtors|13|34,023|25,895|
|Cash at bank||289,792|310,101|
|||323,815|335,996|
|CREDITORS||||
|Amounts
falling due within one year|14|(489302)|(31,384)|
|NET CURRENT ASSETS||275,513|304,612|
|TOTAL ASSETSLESSCURRENT LIABILITIES||1,569,022|1,532,211|
|NET ASSETS||1,569 922|1,532,211|
|FUNDS|15|||
|Unrestricted
funds||1,569,022|1,532,211|
|TOTAL FUNDS||1,569,022|1,532,211|
##
##
##
||||||30.9.23|30.9.22|
|---|---|---|---|---|---|---|
|||||||as restated|
|Other investment
income
Deposit account interest|||||51,186
1,292|46,134
75|
||||||52,478|46,209|
|RAISING FUNDS|||||||
|Investment
management|||costs||||
||||||30.9.23|30.9.22|
|||||||as restated|
|Portfolio|management||||19,451|19,389|
|SUPPORT COSTS|||||||
||||||Governance||
|||||Other|costs|Totals|
|Research|into and education on oncology|||16,360|6,180|22,540|
|NET INCOME/(EXPENDITURE)|||||||
|Net income/(expenditure)||is stated after charging/(crediting):|||||
||||||30.9.23|30.9.22|
|||||||as restated|
|Auditors'|remuneration||||4,560|4,380|
|Auditors'|remuneration|for|non audit work||1,620|1,500|
##
|STAFF COSTS||||||
|---|---|---|---|---|---|
|||||30.9.23|30.9.22|
||||||as restated|
|Wages and salaries||||32,306|21,026|
|||||32,306|21,026|
|Staffcosts are solely|made up ofwages recharged||fi'om various uusts during the year.|||
|The average monthly|number ofemployees|during|the year was as follows:|||
|||||30.9.23|30.9.22|
||||||as restated|
|Research staff|||||2|
##
##
||COMPARATIVES FORTHE STATEMENT OF FINANCIAL ACTIVITIES||
|---|---|---|
|||Unrestricted|
|||fund|
|||as restated|
||INCOME AND ENDOWMENTS FROM||
||Donations
and legacies|17,303|
||Charitable
activities||
||Research into and educafion on oncology|27,129|
||Investment
income
Other income|46,209
8,989|
||Total|99,630|
||EXPENDITURE ON||
||Raising funds|19,389|
||Charitable
activities||
||Research into and education on oncology|49,652|
||Total|69,041|
||Net gains/(losses)
on investments||
||NET INCOME/(EXPENDITURE)|(37,720)|
||RECONCILIATION
OF FUNDS||
||Total funds brought
forward|1,569,931|
||TOTAL FUNDS CARRIED FORWARD|1,532,211|
|10.|PRIOR YEAR ADJUSTMENT||
##
##
|FIXEDASSETINVESTMENTS||
|---|---|
||Listed|
||investments|
|MARKET VALUE||
|At 1October 2022|I/27,599|
|Additions|323,910|
|Disposals|(279,529)|
|Revaluations|21,529|
|At 30 September 2023|1,293,509|
|NET BOOKVALUE||
|At 30 September 2023|1,293,509|
|At 30September 2022|1,227,599|
##
||||||Listed|
|---|---|---|---|---|---|
||||||investments|
||Valuation
Cost|in|2023||Z1,529
7 271,980|
||||||1,293,509|
|13.|DEBTORS:||AMOUNTS FALLING DUE WITHIN ONK YEAR|||
|||||30.9.23|30.9.22|
||||||as restated|
||Other debtors
Prepayments||and accrued income|17,394
16,629|16,446
9,449|
|||||34,023|25,895|
|14,|CREDITORS: AMOUNTS FALLING DUE WITHIN ONK YEAR|||||
|||||30.9.23|30.9.22|
||||||as restated|
||Trade creditors|||33,729|4,652|
||Accrued|expenses||14,573|26,732|
|||||48,302|31,384|
##
##
|||||Gains|Transfers||
|---|---|---|---|---|---|---|
||At|Incoming|Resources|and|between|At|
||01.10.22|resources|expended|losses|funds|30.09.23|
|General
Designated|119,580|10,278|(16,609)|2,667||115,916|
|funds:|||||||
|Breast
Development
Fighting Breast|48&842
93,145|1,632
3112|(1,635)
(1,182)|1,089
2,078||49,928
97,153|
|Cancer
Prof P Hoskin
Dr A Makris
Dr P Ostler
DrKChiu
Dr M Harrison
DrN Shah
Dr D Miles|38/71
582,790
97,511
27,394
184,809
19,110
70,721
102,602|9,630
49,274
3/58
915
11,371
639
2,363
3,428|(5,859)
(48,347)
(7,839)
(1,333)
(15,532)
(243)
(1,567)
(5,100)|856
13,000
2,175
611
4,122
426
1,577
2,288||42,998
596,717
95,105
27,587
184,770
19,932
73,094
103,218|
|Dr SMawdsley
DrRAlonzi|14&804
25,341|495
13,855|(188)
(2,177)|330
565||15,441
37,584|
|Development|73,853|2,467|(938)|1,647||77,029|
|Cyberknife
Fund
Dr Westbury/Guppy
Dr Neel Bhuva|14,244
6,598
9,582|3,587
943
320|(1,463)
(604)
(4,893)|318
147
214||16,686
7,084
5/23|
|Brachy|2&542|85|(32)|57||2,652|
|Dr Anup Vinayan|372|657|~232)|||905|
||1,532,211|118,309|~215,6&3|34,175||1,569,022|
##
|for the Year Ended 3|0Se|tember 2023|||
|---|---|---|---|---|
||||30.9.23|30.9.22|
|||||as restated|
|INCOME AND ENDOWMENTS|||||
|Donations
and legacies|||||
|Donations
Legacies|||28,023
5,000|17,303|
||||33,023|17,303|
|Investment
income|||||
|Other investment
income
Deposit account interest|||51,186
1,292|46,134
75|
||||52,478|46,209|
|Charitable
activities|||||
|Grants|||23,603|27,129|
|Other income|||||
|Training
income
Other income|||2,407
6,798|5,469
3,520|
||||9/05|8,989|
|Total incoming
resources|||1187309|99,630|
|EXPENDITURE|||||
|Investment
management||costs|||
|Portfolio management|||19,451|19,389|
|Charitable
activities|||||
|Research salaries|||32,306|21,026|
|Research materials|||984|6,402|
|Lecture fees|||2,669|466|
|Conference|||25,154|5,004|
|Computer
expenses|||7,517|172|
|Medical equipment|||5,052||
||||737682|33,070|
|Support costs|||||
|Other|||||
|Subscriptions|||1,261|602|
|Administrative
expenses|||7313|6,564|
|Travelling|||40|386|
|Student training|||7,746|3,150|
||||16,360|10,702|
|Governance
costs|||||
|Auditors'
remuneration|||4,560|4,380|
|Auditors'
remuneration||for non audit work|1,620|1,500|
||||6,180|5,880|
|Total resources expended|||~115673|69,041|
|Net income before gains||and losses|2,636|30,589|
|Realised recognised|gains and losses||||
|Realised gains/(losses)|on|fixed asset investments|(35,074)|22,506|
|Net (expenditure)/income|||~32,438)|53,095|